- Poster presentation
- Open Access
Exome sequencing identifies somatic point mutations associated with acquired endocrine resistance in breast cancer cell lines
BMC Proceedings volume 6, Article number: P35 (2012)
Endocrine therapy is an effective treatment of estrogen receptor-positive (ER+) breast tumors, significantly reducing mortality. However, approximately 30% of patients receiving adjuvant endocrine therapy will experience recurrence within a 15-year period. The mechanisms of endocrine resistance are poorly understood. Understanding the underlying genetic diversity of breast cancers responding differently to endocrine therapy is important for the development of more optimal and individualized treatments strategies.
Materials and methods
In the current study, a panel of isogenic MCF-7-derived human breast cancer cell lines [1–3] that are resistant to tamoxifen only, or to both tamoxifen and fulvestrant, respectively, were analyzed for mutations through exome sequencing and compared with the exome of the parental cell line. In addition, global gene expression levels for the same panel of cell lines were generated. Detected variations were integrated with gene expression profiles and analyzed in the context of prior knowledge of drug action and genes associated with resistance to endocrine therapies as identified by extensive literature curation.
Results and conclusion
A small panel of somatic point mutations potentially associated with acquired endocrine resistance were identified. Future experimental validation will reveal which of the detected mutations that are causatively involved in resistance to endocrine therapy.
Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R: Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes butwithout detectable DNA amplifications. Cancer Res. 1993, 53: 283-290.
Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 1993, 53: 3229-3232.
Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fugua SA, Clarke R: MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997, 57: 3486-3493.
About this article
Cite this article
Ehlers, N.S., Da, Z.S., Elias, D. et al. Exome sequencing identifies somatic point mutations associated with acquired endocrine resistance in breast cancer cell lines. BMC Proc 6, P35 (2012). https://doi.org/10.1186/1753-6561-6-S6-P35
- Breast Cancer
- Endocrine Therapy
- Human Breast Cancer
- Breast Cancer Cell Line